Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Lipkowitz

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
The Journal of Biological Chemistry|December 5, 2022
Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growthDavid J Wisniewski, Mariya S Liyasova, Soumya Korrapati, et al.
Cancer Medicine|December 8, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA MutationTakeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz, et al.
Future Oncology (London, England)|April 10, 2020
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastasesAlexandra S Zimmer, Seth M Steinberg, Dee Dee Smart, et al.
Organic Letters|December 14, 2022
Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-BQuan T Khong, Donghao Li, Brice A P Wilson, et al.
Cell Death & Disease|April 25, 2025
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancerKei Kudo, Yoshimi Endo Greer, Daniel R Crooks, et al.
Biorxiv : the Preprint Server for Biology|August 2, 2024
TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancersManjari Kundu, Yoshimi E Greer, Alexei Lobanov, et al.
Molecular Pharmaceutics|March 2, 2017
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsJohn S Schardt, Jinan M Oubaid, Sonya C Williams, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Cancer Letters|April 5, 2025
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cellsManjari Kundu, Yoshimi E Greer, Alexei Lobanov, et al.
Frontiers in Oncology|March 22, 2021
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast CancerMargaret E Gatti-Mays, Sofia R Gameiro, Yohei Ozawa, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Biological Chemistry|December 5, 2022
Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growthDavid J Wisniewski, Mariya S Liyasova, Soumya Korrapati, et al.
Cancer Medicine|December 8, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA MutationTakeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz, et al.
Future Oncology (London, England)|April 10, 2020
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastasesAlexandra S Zimmer, Seth M Steinberg, Dee Dee Smart, et al.
Organic Letters|December 14, 2022
Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-BQuan T Khong, Donghao Li, Brice A P Wilson, et al.
Cell Death & Disease|April 25, 2025
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancerKei Kudo, Yoshimi Endo Greer, Daniel R Crooks, et al.
Biorxiv : the Preprint Server for Biology|August 2, 2024
TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancersManjari Kundu, Yoshimi E Greer, Alexei Lobanov, et al.
Molecular Pharmaceutics|March 2, 2017
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsJohn S Schardt, Jinan M Oubaid, Sonya C Williams, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Cancer Letters|April 5, 2025
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cellsManjari Kundu, Yoshimi E Greer, Alexei Lobanov, et al.
Frontiers in Oncology|March 22, 2021
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast CancerMargaret E Gatti-Mays, Sofia R Gameiro, Yohei Ozawa, et al.
Pageof 11